Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Stocks Give Up Early Gains and Close Lower as Chip Stocks Retreat

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.65%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.18% and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.53%. Stock indexes on Friday gave up early gains and closed moderately lower. Stocks on...

Barchart

Highly Awaited Alzheimer's Drug Hit By Delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

International Business Times

Biogen Surges On A Setback For Eli Lilly's Rival Alzheimer's Treatment

Biogen stock jumped Friday after the FDA delayed its approval decision on Eli Lilly's rival Alzheimer's treatment, donanemab.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

Barchart

Moderna (MRNA) and Biogen (BIIB) - Are There Upsides Left in These Biotech Stocks?

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

StockNews.com

Biogen's Turnaround Is Still Waiting In The Wings As Aduhelm Pressures Continue

Biogen's turnaround is still a "work in progress," an analyst said Tuesday as Biogen stock slumped on light fourth-quarter profit.

Investors Business Daily

Biogen (BIIB): Earnings Alert - Key Insights

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Biogen Pulls Controversial Alzheimer's Drug Aduhelm

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.

International Business Times

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Biotech stocks are heating up as multibillion-dollar deals pile up and new modalities like CRISPR gene-editing hit prime time.

Investors Business Daily

Patent monopolies are not "free" market

Drug patent monopolies cost each family $5,000 per year

Salon

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.

Investors Business Daily

Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review

The stock market rally erased weekly gains as the major indexes ended long win streaks amid rebounding yields. Datadog led earnings winners.

Investors Business Daily

Biogen Skids On 'Low-Quality' Beat, Cuts Profit Guidance Following Reata Buyout

Biogen stock skidded Wednesday on a "low-quality" sales beat that relied on other revenue. But analysts noted Skyclarys' strong launch.

Investors Business Daily

Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment

Biogen stock tumbled Thursday — pulling Prothena stock down — on mixed test results for an updated version of its Alzheimer's treatment.

StockNews.com

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

Investors Business Daily

Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder

Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.

Salon

Do new Alzheimer's drugs actually help?

Fast-track approval of three risky drugs intends to slow the disease, but evidence they benefit patients is shaky

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

FDA Documents Suggest Sage's Battle In Depression Drugs Will Be Trickier Than Expected

Sage said Thursday it will cut about 40% of its workforce following a setback for depression treatment Zurzuvae. Sage stock edged higher.

Investors Business Daily

These Are The 5 Best Stocks Of The Year; Some You May Not Recognize

Reata Pharmaceuticals stock gained 345% this year through Friday and is a top 2023 stock.

Investors Business Daily

Is Eli Lilly Stock A Sell After Its Disastrous Third-Quarter Report?

Is Eli Lilly stock a sell after third-quarter sales of its diabetes and obesity drugs missed forecasts? Is LLY stock a sell?

Investors Business Daily

Stock Market Improves; Tesla Stock Falls On Management Change

The stock market posted gains across the board with the Dow and S&P near the day's highs. Mattel stock gets a lift on "Barbie" movie sales.

The Street

Morningstar's 8 Favorite Healthcare Stocks

The healthcare sector has trailed far behind the overall stock market so far this year, creating 'opportunities.'

Salon

FDA approves postpartum depression pill

Here’s what we know about the second drug to ever be approved for the post-pregnancy condition

The Street

Five Stocks Morningstar Likes After Earnings Reports

Morningstar assigned all five wide moat (durable competitive advantage) ratings and sees them as undervalued.

1 2 3 4 5

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.